Login to Your Account


Revlimid Hits Target in Newly Diagnosed Myeloma Patients

By Catherine Shaffer
Staff Writer

Thursday, July 11, 2013
Celgene International Sarl's successful multiple myeloma drug, Revlimid (lenolidomide), met an important benchmark in newly diagnosed patients in a Phase III study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

NORTH AMERICA
Tel: +1-215-278-8411
Outside of the US
Tel. +44-20-3811-5317
 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2017 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics